{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:32:35Z","timestamp":1762432355729,"version":"3.40.5"},"reference-count":10,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. We examined treatment patterns and healthcare resource utilization (HCRU) and costs among patients with CML treated with dasatinib who experienced a subsequent pleural effusion. Methods: Adults with CML and \u22651 pharmacy claim for dasatinib in 2015\u20132018 who experienced pleural effusion after dasatinib were identified using data from claims databases. Results: Overall, 123 patients were eligible. After 1 year, of the 38.2% of patients with a dose modification, 72.3% did not switch treatment; among these patients, 70.6% continued treatment. Among patients with a stable dose after pleural effusion (61.8%), 57.9% later switched to another TKI. The mean (SD) duration of dasatinib treatment after pleural effusion was 262.0 (124.0) days for patients with a dose modification versus 149.1 (155.2) days for those with a stable dose (p &amp;lt; 0.001). HCRU and costs were similar between groups. Conclusion: Dasatinib dose modification after pleural effusion was not always required; however, patients with dose modifications continued therapy for a longer duration with a lower rate of switching to another TKI versus patients who remained on a stable dose. <\/jats:p>","DOI":"10.1159\/000530512","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T21:00:32Z","timestamp":1681160432000},"page":"259-266","source":"Crossref","is-referenced-by-count":1,"title":["An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy"],"prefix":"10.1159","volume":"146","author":[{"given":"Ali","family":"McBride","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Brokars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila Reiss","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6153","authenticated-orcid":false,"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian H.","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11520"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2372-z"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13524"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0805-1"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.09.012"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1302947"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/146\/4\/259\/3984818\/000530512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/aha\/article-pdf\/146\/4\/259\/3984818\/000530512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:24:48Z","timestamp":1745421888000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000530512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2023,8,15]]}},"URL":"https:\/\/doi.org\/10.1159\/000530512","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.22581949","asserted-by":"subject"}]},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"type":"print","value":"0001-5792"},{"type":"electronic","value":"1421-9662"}],"subject":[],"published":{"date-parts":[[2023]]}}}